First phase 3 trial to prospectively enroll patients with tumors that test positively for TROP2 NMR, a novel computational pathology biomarker to identify those most likely to benefit from Daiichi ...

Topline Data from Three Phase 3 Studies Evaluating DT120 Orally Disintegrating Tablet (ODT) for GAD and MDD Expected in 2026: Voyage in 2Q, Panorama in 2H, and Emerge Mid-Year Company Presenting at ...